How do I search the NADAC pricing database?

Use our free NADAC pricing database to search 60,000+ drugs by name or NDC code. Find weekly price changes, compare manufacturers, and analyze therapeutic class trends all in one place.

How often is NADAC pricing updated?

NADAC prices are updated weekly by the Centers for Medicare & Medicaid Services. Our database is refreshed to reflect the latest price movements within 24 hours of CMS publication.

What is an NDC (National Drug Code)?

An NDC is a unique identifier assigned by the FDA to each drug product. Our NDC lookup tool helps you find NADAC prices and pricing history for specific drug formulations and manufacturers.

NADAC Pricing Lookup
& Drug Pricing Database

Q: What is NADAC pricing?

NADAC (National Average Drug Acquisition Cost) is the weighted average of wholesale prices paid by pharmacies for drugs. Updated weekly by the Centers for Medicare & Medicaid Services (CMS), NADAC pricing is crucial for reimbursement calculations and pharmacy procurement decisions.

Search weekly CMS NADAC prices by drug name or NDC, then analyze market, manufacturer, and class-level trends.

Weekly NADAC pricing brief

Week of August 19, 2026

Read full weekly brief Browse archive

NADAC Weekly Brief: AbbVie's Immunology Portfolio Drives Net Gains as Ustekinumab and Paliperidone Pull Prices Down

For the week ending August 19, 2026, NADAC pricing showed mixed movement across major therapeutic categories. AbbVie Inc. posted the largest aggregate manufacturer swing at $2.9M across 71 products, largely offsetting a $2.1M decline tied to Interleukin-12 Antagonist drugs (Ustekinumab). Risankizumab-rzaa led market-level gains at $2.7M (+0.3%), while Paliperidone Palmitate and Janssen-manufactured products registered notable declines. The Opioid Antagonist class emerged as the most pressured category, rising 1.2% and contributing $870.4K in impact across 107 drugs. Overall market movement remained tight, with most top-mover NDCs shifting less than 1% week-over-week.

Key takeaways

AbbVie Inc. recorded the largest manufacturer-level gain ($2.9M across 71 products), while Janssen Biotech and Janssen Pharmaceuticals both saw declines exceeding $1.1M each.
Interleukin-12 Antagonist (Ustekinumab) drove the week's largest relief at -$2.1M, while Interleukin-23 Antagonist and Risankizumab-rzaa moved in the opposite direction with gains of $860.9K and $2.7M respectively.
Opioid Antagonist was the most pressured therapeutic class this week, up 1.2% and contributing $870.4K in impact across 107 drugs, warranting continued monitoring for formulary and reimbursement impact.

What to watch

Interleukin-12 vs. Interleukin-23 Divergence

Ustekinumab (Interleukin-12 Antagonist) declined $2.1M while Risankizumab-rzaa and Interleukin-23 Antagonist products gained $2.7M and $860.9K respectively. Payers should watch for continued divergence in this competitive immunology space.

GLP-1 Receptor Agonist Softening

The GLP-1 Receptor Agonist class fell 0.9%, a $959.1K impact across 41 drugs. Procurement teams should track whether this downward trend continues into next week's release.

Opioid Antagonist Cost Pressure

This class posted the highest weighted increase this week (+1.2%, $870.4K impact across 107 drugs). Pharmacy and payer teams should monitor for sustained upward pressure in upcoming releases.